Self-Microemulsifying Drug Delivery System to Enhance Oral Bioavailability of Berberine Hydrochloride in Rats
-
Published:2024-08-24
Issue:9
Volume:16
Page:1116
-
ISSN:1999-4923
-
Container-title:Pharmaceutics
-
language:en
-
Short-container-title:Pharmaceutics
Author:
Chen Xiaolan1, Yang Haifeng1, Shi Longyu2, Mao Yujuan1, Niu Lin1, Wang Jing1, Chen Haifeng1, Jia Jiping1, Wang Jingxuan1, Xue Jiajie1, Shen Yan3, Zheng Chunli3, Tian Yu45, Zheng Yi1
Affiliation:
1. Department of Pharmaceutics, Jiangsu Agri-Animal Husbandry Vocational College, No. 8, Fenghuang East Road, Taizhou 225300, China 2. College of Life Sciences, China Pharmaceutical University, Nanjing 210009, China 3. Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China 4. School of Medicine, Shanghai University, Shanghai 200444, China 5. Institute of Geriatrics (Shanghai University), Affiliated Nantong Hospital of Shanghai University (The Sixth People’s Hospital of Nantong), School of Medicine, Shanghai University, Nantong 201613, China
Abstract
Berberine hydrochloride (BH) is a versatile bioactive compound derived from the plants of the Berberis genus, known for its various pharmacological effects. However, its oral bioavailability is low due to its high hydrophilicity and limited permeability. To enhance its clinical efficacy and oral bioavailability, this study designed and prepared a BH-loaded self-microemulsifying drug delivery system (BH-SMEDDS), and characterized its in vitro and in vivo properties. Firstly, the optimal formulation of BH-SMEDDS was selected using solubility evaluations, pseudo-ternary phase diagrams, and particle size analysis. The formulation containing 55% Capmul MCM, 22.5% Kolliphor RH 40, and 22.5% 1,2-propanediol was developed. BH-SMEDDS exhibited stable physicochemical properties, with an average particle size of 47.2 ± 0.10 nm and a self-emulsification time of 26.02 ± 0.24 s. Moreover, in vitro dissolution studies showed significant improvements in BH release in simulated intestinal fluid, achieving 93.1 ± 2.3% release within 300 min. Meanwhile, BH-SMEDDS did not exhibit cytotoxic effects on the Caco-2 cells. Additionally, BH-SMEDDS achieved a 1.63-fold increase in oral bioavailability compared to commercial BH tablets. Therefore, SMEDDS presents a promising strategy for delivering BH with enhanced oral bioavailability, demonstrating significant potential for clinical application.
Funder
Major Project of Basic Science (Natural Science) research in the colleges and universities of Jiangsu Province Qinglan Engineering in Jiangsu Province, Tibet Autonomous Region Science and Technology Department Project Students Innovation and Entrepreneurship Training Program of Vocational College in Jiangsu Province Taizhou Science and Technology Supporting Agriculture Project Jiangsu Agri-animal Husbandry Vocational College Project
Reference33 articles.
1. Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders;Caliceti;Curr. Med. Chem.,2016 2. Nano strategies for berberine delivery, a natural alkaloid of Berberis;Mirhadi;Biomed. Pharmacother. Biomed. Pharmacother.,2018 3. Zhou, J., Dai, Y., Fu, J., Yan, C., Yu, D., and Yi, T. (2023). Dual-step controlled release of berberine hydrochloride from the trans-scale hybrids of nanofibers and microparticles. Biomolecules, 13. 4. Berberine: Alkaloid with wide spectrum of pharmacological activities;Amritpal;J. Nat. Prod.,2010 5. Chen, Y., Li, Q., Zhao, S., Sun, L., Yin, Z., Wang, X., Li, X., Iwakiri, Y., Han, J., and Duan, Y. (2023). Berberine protects mice against type 2 diabetes by promoting PPARγ-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis. Biochem. Pharmacol., 218.
|
|